HUP0303434A3 - Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium - Google Patents

Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium

Info

Publication number: HUP0303434A3
Authority: HU; Hungary
Prior art keywords: atorvastatin calcium; pharmaceutical; composition; pharmaceutical formulation; pharmaceutical form
Prior art date: 2001-03-14

Application number

HU0303434A

Other languages

Hungarian (hu)

Original Assignee

Lek Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-14

Filing date

2002-03-13

Publication date

2011-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0303434(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-13 Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals

2004-01-28 Publication of HUP0303434A2 publication Critical patent/HUP0303434A2/en

2011-09-28 Publication of HUP0303434A3 publication Critical patent/HUP0303434A3/en

2015-10-28 Publication of HU230213B1 publication Critical patent/HU230213B1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HU0303434A 2001-03-14 2002-03-13 Pharmaceutical formulation comprising atorvastatin calcium HU230213B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SI200100069A SI20848A (en)	2001-03-14	2001-03-14	Pharmaceutical formulation containing atorvastatin calcium
SIP-200100069		2001-03-14
PCT/IB2002/000736 WO2002072073A2 (en)	2001-03-14	2002-03-13	Pharmaceutical formulation comprising atorvastatin calcium

Publications (3)

Publication Number	Publication Date
HUP0303434A2 HUP0303434A2 (en)	2004-01-28
HUP0303434A3 true HUP0303434A3 (en)	2011-09-28
HU230213B1 HU230213B1 (en)	2015-10-28

Family

ID=20432850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0303434A HU230213B1 (en)	2001-03-14	2002-03-13	Pharmaceutical formulation comprising atorvastatin calcium

Country Status (25)

Country	Link
US (1)	US7030151B2 (en)
EP (2)	EP2263655B1 (en)
JP (1)	JP4295988B2 (en)
KR (1)	KR100905730B1 (en)
CN (1)	CN1630510B (en)
AT (1)	ATE500818T1 (en)
BG (1)	BG66339B1 (en)
BR (1)	BR0207880A (en)
CA (1)	CA2440331C (en)
CZ (1)	CZ306128B6 (en)
DE (1)	DE60239425D1 (en)
ES (2)	ES2361609T3 (en)
HR (1)	HRP20030726B1 (en)
HU (1)	HU230213B1 (en)
IL (2)	IL157534A0 (en)
ME (1)	ME00517B (en)
MX (1)	MXPA03008340A (en)
PL (2)	PL217835B1 (en)
RS (2)	RS55021B1 (en)
RU (1)	RU2293555C2 (en)
SI (2)	SI20848A (en)
SK (1)	SK287925B6 (en)
UA (1)	UA78201C2 (en)
WO (1)	WO2002072073A2 (en)
ZA (1)	ZA200306575B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE44578E1 (en)	2000-04-10	2013-11-05	Teva Pharmaceutical Industries, Ltd.	Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
DK2382970T3 (en)	2000-04-10	2013-03-25	Teva Pharma	STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPHENIC ACIDS
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ATE420070T1 (en)	2000-12-27	2009-01-15	Teva Pharma	CRYSTALLINE FORMS OF ATORVASTATIN
GEP20053546B (en)	2001-06-29	2005-06-10	Warner Lambert Co	Crystalline Forms of 'R-(R,R)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
US20030175338A1 (en) *	2002-02-14	2003-09-18	Singh Romi Barat	Formulations of atorvastatin stabilized with alkali metal additions
US20070053976A1 (en) *	2002-05-17	2007-03-08	Eisai R & D Management Co., Ltd.	Novel combination of drugs as antidepressant
AU2003298514A1 (en) *	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
CA2385529A1 (en) *	2002-05-21	2003-11-21	Bernard Charles Sherman	Stable dosage forms comprising atorvastatin calcium
SI21302A (en) *	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabilized pharmaceutical product with amorphous active ingredient
SI21402A (en) *	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Lined particles and pharmaceutical forms
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
TR200301614A2 (en) *	2003-09-26	2005-10-21	Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.	New method for the preparation of atorvastatin calcium tablet formulation
CA2564030C (en)	2004-05-05	2010-06-08	Pfizer Products Inc.	Salt forms of [r-(r, r)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2006011041A2 (en)	2004-07-20	2006-02-02	Warner-Lambert Company Llc	Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
RU2007115543A (en) *	2004-10-28	2008-12-10	Уорнер-Ламберт Компани Эл-Эл-Си (US)	METHOD FOR PRODUCING AMORPHOUS ATORVASTATIN
EP1814541A4 (en) *	2004-11-22	2009-10-28	Dexcel Pharma Technologies Ltd	Stable atorvastatin formulations
JP2008521878A (en) *	2004-12-02	2008-06-26	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	Pharmaceutical composition of amorphous atorvastatin and process for its production
ES2263370B1 (en) *	2005-02-16	2007-12-01	Ercros Industrial, S.A.	ATORVASTATINA CALCICA STABILIZED AMORFA AND PROCEDURE FOR OBTAINING IT.
US20080182887A1 (en) *	2005-02-22	2008-07-31	Sun Pharmaceutical Industries Limited	Stable Oral Pharmaceutical Composition
JP5002904B2 (en) *	2005-04-04	2012-08-15	ブラザー工業株式会社	Radio tag communication apparatus, communication method thereof, and communication program thereof
CA2547216A1 (en)	2005-09-21	2007-03-21	Renuka D. Reddy	Process for annealing amorphous atorvastatin
BRPI0520669A2 (en) *	2005-11-21	2009-06-02	Teva Pharma	pharmaceutical dosage that reduces the effect of food found for atorvastatin administration
DE602006014193D1 (en)	2005-11-21	2010-06-17	Warner Lambert Co	NEW FORMS OF A R- (R , R ) U-2- (4-FLUORPHENYL) -B, D-DIHYDROXY-5- (1-METHYLETHYL) -3-PHENYL-4-E (PHENYLAMINO) CARBONYLU-1H- pYRROLE-1-heptanoic MAGNESIUM
EP1923057A1 (en) *	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Atorvastatin pharmaceutical formulation
EP1810667A1 (en) *	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising amorphous atorvastatin
EP1818049A3 (en) *	2006-02-10	2008-11-19	LifeCycle Pharma A/S	Stabilized Atorvastatin
US20080038332A1 (en) *	2006-08-10	2008-02-14	Cai Gu Huang	Stable pharmaceutical formulation comprising atorvastatin calcium
WO2008066185A1 (en) *	2006-12-01	2008-06-05	Nitto Denko Corporation	Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
RU2445953C2 (en) *	2006-12-01	2012-03-27	Нитто Денко Корпорейшн	Stabilised adhesive composition containing donepezil
WO2008112166A2 (en)	2007-03-09	2008-09-18	Indigene Pharmaceuticals Inc.	Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20090226515A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Statin compositions
US20090226516A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Sartan compositions
JP5208209B2 (en) *	2008-05-30	2013-06-12	日東電工株式会社	Donepezil-containing patch preparation and its package
RU2483729C2 (en) *	2008-05-30	2013-06-10	Нитто Денко Корпорейшн	Percutaneously absorbable preparation
WO2010038688A1 (en) *	2008-09-30	2010-04-08	アステラス製薬株式会社	Particulate pharmaceutical composition for oral administration of atorvastatin
MY159533A (en) *	2009-01-02	2017-01-13	Univ Putra Malaysia	Porous bioceramic composition for bone repair
JO3635B1 (en)	2009-05-18	2020-08-27	Millennium Pharm Inc	Solid pharmaceutical compositions and processes for their production
RU2404767C1 (en) *	2009-08-11	2010-11-27	Закрытое Акционерное Общество "БИОКОМ"	Solid dosage form having hypolipidemic and hypocholesteremic activity, and method of its production
KR101248804B1 (en) *	2010-05-14	2013-03-29	한미사이언스 주식회사	BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN
KR20120011249A (en)	2010-07-28	2012-02-07	주식회사 경보제약	Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
CN102755322B (en) *	2012-07-24	2013-12-11	兆科药业（广州）有限公司	Compound preparation of lercanidipine and atorvastatin
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN104069502B (en) *	2013-03-29	2018-02-16	北京罗诺强施医药技术研发中心有限公司	Compound skeleton material and its pharmaceutical composition
CN103705484B (en) *	2014-01-03	2015-05-20	华北制药集团新药研究开发有限责任公司	Stable atorvastatin calcium tablet and preparation methods thereof
CN104013617A (en) *	2014-05-13	2014-09-03	万特制药(海南)有限公司	Composition containing ezetimibe and atorvastatin calcium and preparation method of composition
US10413543B2 (en) *	2015-09-01	2019-09-17	Sun Pharma Advanced Research Company Ltd.	Stable multiparticulate pharmaceutical composition of rosuvastatin
CN119587702A (en) *	2018-04-02	2025-03-11	强生化学制药厂股份有限公司	A pharmaceutical composition capable of improving the bioavailability of oral statins and its use
CN109044989A (en) *	2018-10-09	2018-12-21	河南师范大学	A kind of atorvastatin calcium capsule preparation and preparation method thereof
KR20210098059A (en)	2020-01-31	2021-08-10	주식회사 일원바이오	Composition for preventing, alleviating or treating hyperlipidemia or arteriosclerosis containing extract of Amomum villosum Loureiro as an active ingredient
KR102643099B1 (en)	2020-01-31	2024-03-05	주식회사 일원바이오	Composition for preventing, alleviating or treating hyperlipidemia or arteriosclerosis containing extract of Amomum villosum Loureiro and Atractylodes macrocephala Koidz as an active ingredient
EP4153164A4 (en) *	2020-05-22	2024-06-26	Durect Corporation	Treatment of non-alcoholic steatohepatitis (nash)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (en) *	1989-07-21	1995-08-25	Warner Lambert Co	Process for the preparation of pharmaceutically acceptable [R- (R , R )] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5248793A (en)	1990-10-17	1993-09-28	Warner-Lambert Company	Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DK0680320T3 (en)	1993-01-19	1999-10-25	Warner Lambert Co	Stable oral CI-981 preparation and method of preparation thereof
FR2700452B1 (en)	1993-01-20	1995-03-24	Mgb	Transformable structure for receiving a person's body, for example a cradle for children.
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL128865A (en) *	1995-07-17	2006-04-10	Warner Lambert Co	Crystalline form iv atorvastatin and hydrates thereof, methods for its preparation and pharmacetical compositions containing it
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US5874029A (en)	1996-10-09	1999-02-23	The University Of Kansas	Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6372246B1 (en)	1998-12-16	2002-04-16	Ortho-Mcneil Pharmaceutical, Inc.	Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
SI20109A (en) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stable pharmaceutical formulation
US6696086B1 (en) *	1999-09-10	2004-02-24	Lek Pharmaceuticals D.D.	Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
SI20425A (en)	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Preparation of amorphous atorvastatin
DK2382970T3 (en) *	2000-04-10	2013-03-25	Teva Pharma	STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPHENIC ACIDS
US6806290B2 (en) *	2000-06-09	2004-10-19	Lek Pharmaceuticals D.D.	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
HUP0301325A3 (en) *	2000-06-09	2004-03-01	Lek Pharmaceuticals	Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition

2001
- 2001-03-14 SI SI200100069A patent/SI20848A/en not_active IP Right Cessation
2002
- 2002-02-13 IL IL15753402A patent/IL157534A0/en unknown
- 2002-03-13 UA UA2003098317A patent/UA78201C2/en unknown
- 2002-03-13 BR BR0207880-5A patent/BR0207880A/en not_active Application Discontinuation
- 2002-03-13 WO PCT/IB2002/000736 patent/WO2002072073A2/en active IP Right Grant
- 2002-03-13 SI SI200230945T patent/SI1499297T1/en unknown
- 2002-03-13 PL PL396343A patent/PL217835B1/en unknown
- 2002-03-13 ES ES02702654T patent/ES2361609T3/en not_active Expired - Lifetime
- 2002-03-13 RU RU2003130378/15A patent/RU2293555C2/en active
- 2002-03-13 PL PL371919A patent/PL211803B1/en unknown
- 2002-03-13 CZ CZ2003-2469A patent/CZ306128B6/en not_active IP Right Cessation
- 2002-03-13 US US10/471,906 patent/US7030151B2/en not_active Expired - Lifetime
- 2002-03-13 RS RS20110313A patent/RS55021B1/en unknown
- 2002-03-13 AT AT02702654T patent/ATE500818T1/en not_active IP Right Cessation
- 2002-03-13 HR HRP20030726AA patent/HRP20030726B1/en not_active IP Right Cessation
- 2002-03-13 DE DE60239425T patent/DE60239425D1/en not_active Expired - Lifetime
- 2002-03-13 CA CA002440331A patent/CA2440331C/en not_active Expired - Lifetime
- 2002-03-13 HU HU0303434A patent/HU230213B1/en unknown
- 2002-03-13 ES ES10183122T patent/ES2417881T3/en not_active Expired - Lifetime
- 2002-03-13 JP JP2002571032A patent/JP4295988B2/en not_active Expired - Lifetime
- 2002-03-13 KR KR1020037011535A patent/KR100905730B1/en not_active Expired - Lifetime
- 2002-03-13 ME MEP-2008-845A patent/ME00517B/en unknown
- 2002-03-13 SK SK1136-2003A patent/SK287925B6/en unknown
- 2002-03-13 EP EP10183122.0A patent/EP2263655B1/en not_active Expired - Lifetime
- 2002-03-13 CN CN028064739A patent/CN1630510B/en not_active Expired - Lifetime
- 2002-03-13 MX MXPA03008340A patent/MXPA03008340A/en active IP Right Grant
- 2002-03-13 RS YU69603A patent/RS51746B/en unknown
- 2002-03-13 EP EP02702654A patent/EP1499297B1/en not_active Expired - Lifetime
2003
- 2003-08-21 IL IL157534A patent/IL157534A/en active IP Right Grant
- 2003-08-22 ZA ZA200306575A patent/ZA200306575B/en unknown
- 2003-09-12 BG BG108175A patent/BG66339B1/en unknown

Also Published As

Publication number	Publication date
HRP20030726A2 (en)	2005-04-30
IL157534A (en)	2009-12-24
SK11362003A3 (en)	2004-02-03
BG66339B1 (en)	2013-07-31
PL371919A1 (en)	2005-07-11
RS20110313A (en)	2011-10-31
SI20848A (en)	2002-10-31
ZA200306575B (en)	2004-09-30
BG108175A (en)	2004-09-30
CN1630510A (en)	2005-06-22
PL396343A1 (en)	2012-01-16
RS55021B1 (en)	2016-11-30
CA2440331C (en)	2008-05-06
ATE500818T1 (en)	2011-03-15
YU69603A (en)	2006-05-25
RU2003130378A (en)	2005-04-10
EP2263655A1 (en)	2010-12-22
IL157534A0 (en)	2004-03-28
CZ20032469A3 (en)	2004-09-15
ME00517B (en)	2011-10-10
HRP20030726B1 (en)	2013-04-30
RU2293555C2 (en)	2007-02-20
WO2002072073A3 (en)	2004-05-13
CZ306128B6 (en)	2016-08-17
SK287925B6 (en)	2012-04-03
PL217835B1 (en)	2014-08-29
EP1499297A2 (en)	2005-01-26
JP2004533999A (en)	2004-11-11
HU230213B1 (en)	2015-10-28
US7030151B2 (en)	2006-04-18
CN1630510B (en)	2012-04-04
HUP0303434A2 (en)	2004-01-28
EP1499297B1 (en)	2011-03-09
ES2417881T3 (en)	2013-08-09
MXPA03008340A (en)	2004-10-15
EP2263655B1 (en)	2013-04-24
ES2361609T3 (en)	2011-06-20
RS51746B (en)	2011-10-31
KR100905730B1 (en)	2009-07-01
CA2440331A1 (en)	2002-09-19
US20040138290A1 (en)	2004-07-15
UA78201C2 (en)	2007-03-15
PL211803B1 (en)	2012-06-29
WO2002072073A2 (en)	2002-09-19
DE60239425D1 (en)	2011-04-21
KR20040025901A (en)	2004-03-26
JP4295988B2 (en)	2009-07-15
BR0207880A (en)	2004-03-02
SI1499297T1 (en)	2011-07-29

Publication	Publication Date	Title
HUP0303434A3 (en)	2011-09-28	Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium
HUS1400025I1 (en)	2016-08-29	Phenethanolamine derivatives and pharmaceutical composition containing them
HUP0303325A3 (en)	2008-03-28	Pharmaceutical salts and pharmaceutical compositions containing them
IL152659A0 (en)	2003-06-24	Pharmaceutical composition
GB0102342D0 (en)	2001-03-14	Pharmaceutical formulation
SI1524266T1 (en)	2007-08-31	Pharmaceutical composition
HUP0301042A3 (en)	2010-03-29	Pharmaceutical composition useful in contraception
HUP0204555A3 (en)	2004-06-28	Pharmaceutical composition
GB0118689D0 (en)	2001-09-19	Pharmaceutical formulation
GB0108470D0 (en)	2001-05-23	Pharmaceutical compositions and their use
IL154238A0 (en)	2003-09-17	Pharmaceutical composition
HUP0401644A3 (en)	2008-03-28	Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
HUP0401713A3 (en)	2012-08-28	Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
IL153176A (en)	2012-10-31	Phenylpiperazines and pharmaceutical compositions comprising them
GB0013503D0 (en)	2000-07-26	Pharmaceutical compositions and their uses
GB0005382D0 (en)	2000-04-26	Pharmaceutical composition
GB0014851D0 (en)	2000-08-09	Novel pharmaceutical formulation
HUP0303688A3 (en)	2005-06-28	Propanolaminotetralines, preparation thereof and pharmaceutical compositions containing same
GB0014947D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0014883D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0000001D0 (en)	2000-02-23	Pharmaceutical compositions and their preparation
GB0014869D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0104749D0 (en)	2001-04-18	Pharmaceutical formulation
HU0102982D0 (en)	2001-09-28	Synergic pharmaceutical composition
EP1414417A4 (en)	2004-05-06	Pharmaceutical formulation

Legal Events

Date	Code	Title	Description
2010-07-28	HC9A	Change of name, address	Owner name: LEK PHARMACEUTICALS D.D., SI Free format text: FORMER OWNER(S): LEK PHARMACEUTICAL AND CHEMICAL CO. D.D., SI

Date

Code

Title

Description

2010-07-28

HC9A

Change of name, address

Owner name: LEK PHARMACEUTICALS D.D., SI

Free format text: FORMER OWNER(S): LEK PHARMACEUTICAL AND CHEMICAL CO. D.D., SI